The combination of ramucirumab with trifluridine/tipiracil failed to show improvements in overall survival vs TAS-102 alone ...

Merit Medical Systems, IncMMSI announced favorable 6-month results from the randomized arteriovenous (AV) fistula arm of its ...

David A. Eichenbaum, MD, presented key data from two clinical trials focusing on therapies for age-related macular ...

In an international multicenter randomized phase 3 clinical trial led by Dana-Farber Cancer Institute, researchers tested the ...

Treatment with Cyramza plus Lonsurf did not improve overall survival compared with Lonsurf alone in heavily pretreated ...

Tivozanib Plus Nivolumab vs Tivozanib Monotherapy in Patients with Renal Cell Carcinoma Following an Immune Checkpoint ...

The scientific name for rosemary is Rosmarinus officinalis. It is a small evergreen plant that is part of the mint family, ...

India can be a top turmeric supplier for global nutraceuticals. Standardised farming and post-harvest practices are a must ...

In an international multicenter randomized phase 3 clinical trial led by Dana-Farber Cancer Institute, researchers tested the addition of the immune checkpoint inhibitor (ICI) nivolumab to treatment ...

Adding bevacizumab to the combination therapy of carboplatin and paclitaxel significantly improved progression-free survival ...

北京时间9月13日，备受瞩目的2024年欧洲肿瘤内科学会（ESMO）大会在西班牙巴塞罗那盛大开幕。作为全球肿瘤学领域最具影响力的盛会之一，本次大会吸引了众多世界顶级专家汇聚一堂，共同探讨和分享肿瘤学领域的最新科研成果与治疗技术。

作为创新型国际化制药企业，恒瑞医药长期坚持“科技为本，为人类创造健康生活”的使命，针对肿瘤等严重威胁人类生命健康的疾病开展科研攻关，已上市的17款1类创新药中抗肿瘤创新药达9款。公司另有90多个自主创新产品正在临床开发，300余项临床试验在国内外开展。本次ESMO大会，公司携13款创新药的37项抗肿瘤领域研究登上国际学术舞台，奏响了抗肿瘤领域自主创新实力的强音，也是中国医药研发创新力量的展现。